Denali’s wholly owned program, DNL310 or tividenofusp alfa, is an Enzyme Transport Vehicle-enabled iduronate-2-sulfatase (IDS) replacement therapy in development for MPS II (Hunter syndrome).

This designation is in addition to Fast Track Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation, all previously granted by the FDA for tividenofusp alfa in Hunter syndrome.

Hunter syndrome affects over 2,000 individuals, primarily males, in commercially accessible regions. With analysts maintaining a Strong Buy consensus and the company maintaining a healthy liquidity ...

Abstract: Skin lesion segmentation is critical in medical image processing, but the segmentation task faces numerous challenges due to the differences in size, color, shape, and texture of skin ...

skin, sputum, testes and veins. "The alarming link between [microplastics and nanoplastics] occurrence to human tissue lesions and even cancer has attracted scientists’ attention." The authors ...

He was as goaded and restive at the age of 100 as he was 50 years ago, when he gave the “king hell bastard of a speech” citing Reinhold Niebuhr and Bob Dylan that so impressed Hunter Thompson.